1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd.

SHTDF
Sinopharm Group Co. Ltd.US flagOther OTC
2.13
USD
- -
- -
6.65BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
66.13
77.41
82.63
93.53
103.75
116.09
143.11
146.7
167.48
176.93
191.17
187.3
184.31
46.96
Basic EPS, GAAP
0.89
1.11
1.36
1.68
1.88
1.97
2.1
2.31
2.49
2.73
2.9
2.26
2.29
0.65
Free Cash Flow per Basic Share
1.44
1.42
4.38
2.86
0.32
0.08
5.46
2.91
2.27
5.94
4.75
3.07
4.01
-0.42
Dividend per Share
0.25
0.26
0.31
0.41
0.47
0.53
0.59
0.6
0.69
0.75
0.82
0.87
0.68
- -
Book Value per Share
3.12
1.07
4.63
5.87
0.93
1
1
1
1
14.75
16.83
18.22
19.84
17.34
Tangible Book Value per Share
9.12
11.58
12.34
13.86
17.1
20.48
22.26
24.87
28.11
31.42
34.7
37.08
39.74
36.38
Basic Weighted Avg Shares
2,523
2,585
2,767
2,760
2,965
2,968
2,972
3,111
3,111
3,121
3,121
3,121
3,121
3,087
Sales/Revenue/Turnover
166,866
200,131
228,633
258,117
307,666
344,526
425,273
456,415
521,051
552,148
596,570
584,508
575,168
144,969
Operating Margin (%)
3.66
3.93
4.02
3.85
4.05
4.57
4.35
4.33
4.03
4.08
3.73
3.04
2.97
3.46
Depreciation Expense
677
835
1,006
1,068
1,240
1,395
3,114
3,597
3,922
4,165
4,430
4,734
4,289
- -
Net Income, GAAP
2,250
2,875
3,772
4,647
5,576
5,836
6,253
7,187
7,759
8,526
9,054
7,050
7,155
1,992
Effective Tax Rate (%)
22.53
23.3
23.14
22.78
22.82
22.96
22.82
22.44
23.16
22.72
23.07
25.55
26.79
23.72
Profit Margin (%)
1.35
1.44
1.65
1.8
1.81
1.69
1.47
1.57
1.49
1.54
1.52
1.21
1.24
1.37
Working Capital
18,872
24,253
22,278
33,022
38,188
44,580
51,575
63,633
71,616
84,443
95,344
97,072
100,070
99,125
LT Debt
4,134
4,223
608
11,135
5,594
5,019
11,470
12,162
11,669
14,957
17,255
11,897
6,141
19,606
Total Equity
28,611
36,290
40,879
44,532
57,947
68,276
76,939
89,947
99,654
110,069
120,319
126,687
134,160
122,433
Return on Invested Capital (%)
10.04
9.96
10.35
10.29
10.91
10.92
10.99
10.39
9.72
9.84
9.02
6.57
6.05
- -
Return on Capital (%)
7.06
7.11
7.28
6.93
7.61
6.47
5.31
5.12
4.98
4.07
3.26
3.23
2.83
4.45
Return on Common Equity (%)
43.76
54
48.46
32.04
58.78
203.38
210.41
235.95
248.62
34.69
18.37
12.89
12.05
470.76

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
ST Debt
- -
81,450
LT Borrowings
- -
15,925
LT Finance Leases
- -
3,680
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
- -
3,121
Market Capitalization
58,255
60,596

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Total Current Assets
- -
382,363
Cash, Cash Equivalents & STI
- -
43,332
Accounts Receivable, Net
- -
234,307
Inventories
- -
68,838
Total Current Liabilities
- -
283,238
Payables & Accruals
- -
- -
ST Debt
- -
81,450
Deferred Revenue
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.82%
8.35%
5.9%
Free Cash Flow
627.68%
23.21%
30.73%
Net Income, GAAP
7.33%
0.68%
1.5%
Sales/Revenue/Turnover
9.94%
4.91%
-1.6%
Total Cash Common Dividend
10.35%
3.55%
-21.84%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
144,969
- -
- -
596,570
2024
- -
- -
- -
- -
584,508
2025
- -
- -
- -
- -
575,168

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.9
2024
- -
- -
- -
- -
2.26
2025
- -
- -
- -
- -
2.29

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.82
2024
- -
- -
- -
- -
0.87
2025
- -
- -
- -
- -
0.68

Company Description

APIChatGPT
CEO
Wanyong Lian
Full Time Employees
94,910
Sector
Healthcare
Industry
Medical - Distribution
Address
Sinopharm Group Building Shanghai SH People's Republic of China 200023
IPO Date
Apr 21, 2011
Website
sinopharmgroup.com.cn
Similar Companies
Entero Healthcare Solutions Limited (ENTERO.NS)
China Meheco Group Co., Ltd. (600056.SS)
China Health Group Limited (0673.HK)
DH Enchantment Inc. (ENMI)
DocMorris AG (ZRSEF)
Alfresa Holdings Corporation (ARHCF)
Business
Sinopharm Group Co. Ltd. Sinopharm Group Co. Ltd. engages in the wholesale and retail distribution of pharmaceutical products, medical devices, and healthcare items primarily in China. The company operates through key segments including pharmaceutical distribution, which supplies drugs such as antibiotics, biological products, and Chinese herbal medicines to hospitals, clinics, distributors, and retail pharmacies while providing logistics and value-added services; medical devices distribution, encompassing installation, maintenance, and sales of equipment; retail pharmacy, managing and franchising a nationwide network of drug stores; and other businesses involving laboratory supplies, chemical reagents manufacturing, property management, and pharmaceutical production. It also offers information technology, import-export, consulting, and exhibition services, with operations centered in China and exports worldwide. Founded in 2003 as a subsidiary of China National Pharmaceutical Group Co. Ltd., a state-owned enterprise established in 1998 and headquartered at 20 Zhichun Road, Haidian District, Beijing, China, Sinopharm Group Co. Ltd. maintains its principal operations from Shanghai. The company serves diverse customers including healthcare providers, manufacturers, and consumers through an extensive supply chain focused on life and health industries. Recent developments include a deep strategic cooperation agreement signed on December 13, 2024, with China Biopharmaceutical to integrate resources in retail pharmacy, national university pharmacy, and professional services, aiming to build a nationwide off-hospital market network and enhance patient access. In December 2024, its subsidiary Hupan Pharmaceutical entered a $1.5 million sales agreement with Sinopharm Holding Hubei New Special Medicine Co., Ltd. for essential medicine supply following prior logistics partnerships. Additionally, in April 2023, it formed a cooperation pact with Pfizer to seek approvals for 12 drugs in China by 2025, bolstering its portfolio amid ongoing expansions in distribution and manufacturing.

Company News

APIChatGPT

  • defenseworld.net

    Sinopharm Group (OTCMKTS:SHTDF) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

  • defenseworld.net

    Sinopharm Group (OTCMKTS:SHTDF) Stock Price Passes Above 50 Day Moving Average – Time to Sell?